Immunotherapy improves the prognosis of babies with a very aggressive leukemia

A trial with thirty patients under one year of age confirms that adding a bispecific antibody to the chemotherapy treatment increases the survival rates of a subtype of blood cancer from 66% to 93%.

Read more: https://english.elpais.com/science-tech/2023-04-27/immunotherapy-improves-the-prognosis-of-babies-with-a-very-aggressive-leukemia.html